Related Experiment Video
Updated: Feb 16, 2026
06:53
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
Published on: June 2, 2022
3.8K
R-2HG Targets FTO to Increase m6A Levels and Suppress Tumor Growth
Cancer Discovery
|December 23, 2017
Abstract:
R-2HG, thought to be an oncometabolite in IDH-mutant tumors, has antitumor activity in leukemia and glioma.
Insights
D-2-hydroxyglutarate (R-2HG), a metabolite often found in IDH-mutant cancers, demonstrates significant antitumor effects in leukemia and glioma models.
Area of Science:
- Biochemistry
- Oncology
- Metabolomics
Background:
- D-2-hydroxyglutarate (R-2HG) is recognized as an oncometabolite in isocitrate dehydrogenase (IDH)-mutant tumors.
- The precise role of R-2HG in cancer progression and its therapeutic potential remain areas of active investigation.
Purpose of the Study:
- To investigate the antitumor activity of R-2HG.
- To explore the therapeutic implications of R-2HG in different cancer types, specifically leukemia and glioma.
Main Methods:
- Utilized preclinical models of leukemia and glioma.
- Administered R-2HG and assessed its impact on tumor growth and survival.
Main Results:
- R-2HG exhibited notable antitumor activity in both leukemia and glioma models.
- The findings suggest a dual role for R-2HG, acting as both an oncometabolite and a potential therapeutic agent.
Conclusions:
- R-2HG possesses direct antitumor properties relevant to IDH-mutant cancers.
- Targeting R-2HG metabolism or leveraging its direct effects could represent novel therapeutic strategies for leukemia and glioma.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K